Prostatype Genomics AB Cash Flow Conversion Efficiency
Prostatype Genomics AB cash flow conversion efficiency. Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has a cash flow conversion efficiency ratio of -0.234x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.54 Million ≈ $-918.99K USD) by net assets (Skr36.48 Million ≈ $3.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Prostatype Genomics AB (2016–2024)
Cash flow conversion efficiency of Prostatype Genomics AB from 2016 to 2024. This chart illustrates how Prostatype Genomics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PROGEN share price today for real-time trading data and today's change.
Prostatype Genomics AB Cash Flow Conversion Ratio Explained
Prostatype Genomics AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Prostatype Genomics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prostatype Genomics AB ranked by their cash flow conversion efficiency. Also see Prostatype Genomics AB (PROGEN) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GOLDSTONE RES LTD. LS-01
F:GVL1
|
N/A |
|
GenixPharmaceucticals Corporation
V:GENX
|
0.011x |
|
Fort St James Nickel Corp
V:FTJ
|
0.010x |
|
Creo Medical Group PLC
LSE:CREO
|
-0.684x |
|
VSee Health, Inc.
NASDAQ:VSEE
|
-0.353x |
|
Gemfields Plc
LSE:GEM
|
0.044x |
|
Real Estate Investors PLC
LSE:RLE
|
0.016x |
|
Tinybuild Inc
LSE:TBLD
|
0.161x |
Annual Cash Flow Conversion Efficiency for Prostatype Genomics AB (2016–2024)
The table below shows the annual cash flow conversion efficiency of Prostatype Genomics AB from 2016 to 2024. Review Prostatype Genomics AB (PROGEN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr33.47 Million ≈ $3.60 Million |
Skr-44.71 Million ≈ $-4.81 Million |
-1.336x | -13.12% |
| 2023-12-31 | Skr24.67 Million ≈ $2.66 Million |
Skr-29.14 Million ≈ $-3.14 Million |
-1.181x | -11.52% |
| 2022-12-31 | Skr26.15 Million ≈ $2.81 Million |
Skr-27.69 Million ≈ $-2.98 Million |
-1.059x | -136.49% |
| 2021-12-31 | Skr35.91 Million ≈ $3.86 Million |
Skr-16.08 Million ≈ $-1.73 Million |
-0.448x | +13.89% |
| 2020-12-31 | Skr28.29 Million ≈ $3.04 Million |
Skr-14.71 Million ≈ $-1.58 Million |
-0.520x | +53.85% |
| 2018-12-31 | Skr8.55 Million ≈ $919.74K |
Skr-9.63 Million ≈ $-1.04 Million |
-1.127x | -22.82% |
| 2017-12-31 | Skr6.22 Million ≈ $669.69K |
Skr-5.71 Million ≈ $-614.46K |
-0.918x | -42.21% |
| 2016-12-31 | Skr14.93 Million ≈ $1.61 Million |
Skr-9.63 Million ≈ $-1.04 Million |
-0.645x | -- |
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more